articleThe LancetJun 3, 2016Closed access

Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)

KUKatsuhiko UesakaNBNarikazu BokuAFAkira FukutomiYOYukiyasu OkamuraMKMasaru Konishi

Shizuoka Cancer Center · Tokyo National Hospital · +18 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

1,121
total citations
FWCI
49.84
Percentile
100%
References
26
Citations per year

Authors

20

Topics & keywords

Topics
Keywords
  • Gemcitabine
  • Medicine
  • Pancreatic cancer
  • Internal medicine
  • Chemotherapy
  • Population
  • Surgery
  • Cancer
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding